nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000575	0.000575	CcSEcCtD
Gadoversetamide—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000574	0.000574	CcSEcCtD
Gadoversetamide—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000572	0.000572	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000571	0.000571	CcSEcCtD
Gadoversetamide—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000563	0.000563	CcSEcCtD
Gadoversetamide—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000561	0.000561	CcSEcCtD
Gadoversetamide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000559	0.000559	CcSEcCtD
Gadoversetamide—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000558	0.000558	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000558	0.000558	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000557	0.000557	CcSEcCtD
Gadoversetamide—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000552	0.000552	CcSEcCtD
Gadoversetamide—Pain—Cisplatin—peripheral nervous system neoplasm	0.000552	0.000552	CcSEcCtD
Gadoversetamide—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.00055	0.00055	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.00055	0.00055	CcSEcCtD
Gadoversetamide—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000545	0.000545	CcSEcCtD
Gadoversetamide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000543	0.000543	CcSEcCtD
Gadoversetamide—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000539	0.000539	CcSEcCtD
Gadoversetamide—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000539	0.000539	CcSEcCtD
Gadoversetamide—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000539	0.000539	CcSEcCtD
Gadoversetamide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000538	0.000538	CcSEcCtD
Gadoversetamide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000536	0.000536	CcSEcCtD
Gadoversetamide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000532	0.000532	CcSEcCtD
Gadoversetamide—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000531	0.000531	CcSEcCtD
Gadoversetamide—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000527	0.000527	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000526	0.000526	CcSEcCtD
Gadoversetamide—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000525	0.000525	CcSEcCtD
Gadoversetamide—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000524	0.000524	CcSEcCtD
Gadoversetamide—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000523	0.000523	CcSEcCtD
Gadoversetamide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000519	0.000519	CcSEcCtD
Gadoversetamide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000518	0.000518	CcSEcCtD
Gadoversetamide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000515	0.000515	CcSEcCtD
Gadoversetamide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000514	0.000514	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00051	0.00051	CcSEcCtD
Gadoversetamide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00051	0.00051	CcSEcCtD
Gadoversetamide—Fatigue—Etoposide—peripheral nervous system neoplasm	0.00051	0.00051	CcSEcCtD
Gadoversetamide—Pain—Etoposide—peripheral nervous system neoplasm	0.000505	0.000505	CcSEcCtD
Gadoversetamide—Constipation—Etoposide—peripheral nervous system neoplasm	0.000505	0.000505	CcSEcCtD
Gadoversetamide—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000505	0.000505	CcSEcCtD
Gadoversetamide—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000505	0.000505	CcSEcCtD
Gadoversetamide—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000504	0.000504	CcSEcCtD
Gadoversetamide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000501	0.000501	CcSEcCtD
Gadoversetamide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000499	0.000499	CcSEcCtD
Gadoversetamide—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000495	0.000495	CcSEcCtD
Gadoversetamide—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.00049	0.00049	CcSEcCtD
Gadoversetamide—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000487	0.000487	CcSEcCtD
Gadoversetamide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000487	0.000487	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000486	0.000486	CcSEcCtD
Gadoversetamide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000485	0.000485	CcSEcCtD
Gadoversetamide—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000483	0.000483	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000483	0.000483	CcSEcCtD
Gadoversetamide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000483	0.000483	CcSEcCtD
Gadoversetamide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000481	0.000481	CcSEcCtD
Gadoversetamide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000477	0.000477	CcSEcCtD
Gadoversetamide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000477	0.000477	CcSEcCtD
Gadoversetamide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000475	0.000475	CcSEcCtD
Gadoversetamide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000474	0.000474	CcSEcCtD
Gadoversetamide—Urticaria—Etoposide—peripheral nervous system neoplasm	0.00047	0.00047	CcSEcCtD
Gadoversetamide—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000469	0.000469	CcSEcCtD
Gadoversetamide—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000468	0.000468	CcSEcCtD
Gadoversetamide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000467	0.000467	CcSEcCtD
Gadoversetamide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000467	0.000467	CcSEcCtD
Gadoversetamide—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000467	0.000467	CcSEcCtD
Gadoversetamide—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000467	0.000467	CcSEcCtD
Gadoversetamide—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000466	0.000466	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000464	0.000464	CcSEcCtD
Gadoversetamide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000464	0.000464	CcSEcCtD
Gadoversetamide—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000463	0.000463	CcSEcCtD
Gadoversetamide—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000463	0.000463	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000461	0.000461	CcSEcCtD
Gadoversetamide—Rash—Vincristine—peripheral nervous system neoplasm	0.00046	0.00046	CcSEcCtD
Gadoversetamide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00046	0.00046	CcSEcCtD
Gadoversetamide—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000459	0.000459	CcSEcCtD
Gadoversetamide—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000458	0.000458	CcSEcCtD
Gadoversetamide—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000457	0.000457	CcSEcCtD
Gadoversetamide—Headache—Vincristine—peripheral nervous system neoplasm	0.000457	0.000457	CcSEcCtD
Gadoversetamide—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000453	0.000453	CcSEcCtD
Gadoversetamide—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000451	0.000451	CcSEcCtD
Gadoversetamide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00045	0.00045	CcSEcCtD
Gadoversetamide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000441	0.000441	CcSEcCtD
Gadoversetamide—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000441	0.000441	CcSEcCtD
Gadoversetamide—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000436	0.000436	CcSEcCtD
Gadoversetamide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000435	0.000435	CcSEcCtD
Gadoversetamide—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000435	0.000435	CcSEcCtD
Gadoversetamide—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000434	0.000434	CcSEcCtD
Gadoversetamide—Nausea—Vincristine—peripheral nervous system neoplasm	0.000433	0.000433	CcSEcCtD
Gadoversetamide—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000433	0.000433	CcSEcCtD
Gadoversetamide—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000433	0.000433	CcSEcCtD
Gadoversetamide—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000433	0.000433	CcSEcCtD
Gadoversetamide—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000432	0.000432	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000429	0.000429	CcSEcCtD
Gadoversetamide—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000428	0.000428	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000426	0.000426	CcSEcCtD
Gadoversetamide—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000425	0.000425	CcSEcCtD
Gadoversetamide—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000424	0.000424	CcSEcCtD
Gadoversetamide—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000423	0.000423	CcSEcCtD
Gadoversetamide—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000423	0.000423	CcSEcCtD
Gadoversetamide—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000421	0.000421	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00042	0.00042	CcSEcCtD
Gadoversetamide—Chills—Epirubicin—peripheral nervous system neoplasm	0.000418	0.000418	CcSEcCtD
Gadoversetamide—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000418	0.000418	CcSEcCtD
Gadoversetamide—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000417	0.000417	CcSEcCtD
Gadoversetamide—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00041	0.00041	CcSEcCtD
Gadoversetamide—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000409	0.000409	CcSEcCtD
Gadoversetamide—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000408	0.000408	CcSEcCtD
Gadoversetamide—Rash—Cisplatin—peripheral nervous system neoplasm	0.000407	0.000407	CcSEcCtD
Gadoversetamide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000406	0.000406	CcSEcCtD
Gadoversetamide—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000406	0.000406	CcSEcCtD
Gadoversetamide—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000406	0.000406	CcSEcCtD
Gadoversetamide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000404	0.000404	CcSEcCtD
Gadoversetamide—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000403	0.000403	CcSEcCtD
Gadoversetamide—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000402	0.000402	CcSEcCtD
Gadoversetamide—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.0004	0.0004	CcSEcCtD
Gadoversetamide—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.0004	0.0004	CcSEcCtD
Gadoversetamide—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.0004	0.0004	CcSEcCtD
Gadoversetamide—Tension—Epirubicin—peripheral nervous system neoplasm	0.000398	0.000398	CcSEcCtD
Gadoversetamide—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000398	0.000398	CcSEcCtD
Gadoversetamide—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000394	0.000394	CcSEcCtD
Gadoversetamide—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000393	0.000393	CcSEcCtD
Gadoversetamide—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000392	0.000392	CcSEcCtD
Gadoversetamide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000391	0.000391	CcSEcCtD
Gadoversetamide—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.00039	0.00039	CcSEcCtD
Gadoversetamide—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00039	0.00039	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000389	0.000389	CcSEcCtD
Gadoversetamide—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000387	0.000387	CcSEcCtD
Gadoversetamide—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000385	0.000385	CcSEcCtD
Gadoversetamide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000383	0.000383	CcSEcCtD
Gadoversetamide—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000383	0.000383	CcSEcCtD
Gadoversetamide—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000378	0.000378	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000377	0.000377	CcSEcCtD
Gadoversetamide—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000376	0.000376	CcSEcCtD
Gadoversetamide—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000376	0.000376	CcSEcCtD
Gadoversetamide—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000376	0.000376	CcSEcCtD
Gadoversetamide—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000373	0.000373	CcSEcCtD
Gadoversetamide—Rash—Etoposide—peripheral nervous system neoplasm	0.000373	0.000373	CcSEcCtD
Gadoversetamide—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000372	0.000372	CcSEcCtD
Gadoversetamide—Headache—Etoposide—peripheral nervous system neoplasm	0.00037	0.00037	CcSEcCtD
Gadoversetamide—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.00037	0.00037	CcSEcCtD
Gadoversetamide—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000369	0.000369	CcSEcCtD
Gadoversetamide—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000368	0.000368	CcSEcCtD
Gadoversetamide—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000366	0.000366	CcSEcCtD
Gadoversetamide—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000365	0.000365	CcSEcCtD
Gadoversetamide—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000365	0.000365	CcSEcCtD
Gadoversetamide—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000364	0.000364	CcSEcCtD
Gadoversetamide—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000363	0.000363	CcSEcCtD
Gadoversetamide—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000361	0.000361	CcSEcCtD
Gadoversetamide—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000359	0.000359	CcSEcCtD
Gadoversetamide—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000357	0.000357	CcSEcCtD
Gadoversetamide—Cough—Epirubicin—peripheral nervous system neoplasm	0.000354	0.000354	CcSEcCtD
Gadoversetamide—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000354	0.000354	CcSEcCtD
Gadoversetamide—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000352	0.000352	CcSEcCtD
Gadoversetamide—Nausea—Etoposide—peripheral nervous system neoplasm	0.000351	0.000351	CcSEcCtD
Gadoversetamide—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000351	0.000351	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000349	0.000349	CcSEcCtD
Gadoversetamide—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000346	0.000346	CcSEcCtD
Gadoversetamide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000346	0.000346	CcSEcCtD
Gadoversetamide—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000346	0.000346	CcSEcCtD
Gadoversetamide—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.000345	CcSEcCtD
Gadoversetamide—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000344	0.000344	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000343	0.000343	CcSEcCtD
Gadoversetamide—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000341	0.000341	CcSEcCtD
Gadoversetamide—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000339	0.000339	CcSEcCtD
Gadoversetamide—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000338	0.000338	CcSEcCtD
Gadoversetamide—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000337	0.000337	CcSEcCtD
Gadoversetamide—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000337	0.000337	CcSEcCtD
Gadoversetamide—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000334	0.000334	CcSEcCtD
Gadoversetamide—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000332	0.000332	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000331	0.000331	CcSEcCtD
Gadoversetamide—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000331	0.000331	CcSEcCtD
Gadoversetamide—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.00033	0.00033	CcSEcCtD
Gadoversetamide—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000328	0.000328	CcSEcCtD
Gadoversetamide—Shock—Epirubicin—peripheral nervous system neoplasm	0.000326	0.000326	CcSEcCtD
Gadoversetamide—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000325	0.000325	CcSEcCtD
Gadoversetamide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000325	0.000325	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000324	0.000324	CcSEcCtD
Gadoversetamide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000324	0.000324	CcSEcCtD
Gadoversetamide—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000323	0.000323	CcSEcCtD
Gadoversetamide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000322	0.000322	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.00032	0.00032	CcSEcCtD
Gadoversetamide—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.00032	CcSEcCtD
Gadoversetamide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.00032	CcSEcCtD
Gadoversetamide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.00032	CcSEcCtD
Gadoversetamide—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000319	0.000319	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000318	CcSEcCtD
Gadoversetamide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000316	0.000316	CcSEcCtD
Gadoversetamide—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000316	0.000316	CcSEcCtD
Gadoversetamide—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000313	0.000313	CcSEcCtD
Gadoversetamide—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.00031	0.00031	CcSEcCtD
Gadoversetamide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000309	0.000309	CcSEcCtD
Gadoversetamide—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000307	0.000307	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000307	0.000307	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000302	0.000302	CcSEcCtD
Gadoversetamide—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000302	0.000302	CcSEcCtD
Gadoversetamide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000301	0.000301	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.0003	0.0003	CcSEcCtD
Gadoversetamide—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.0003	0.0003	CcSEcCtD
Gadoversetamide—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.000299	CcSEcCtD
Gadoversetamide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000298	0.000298	CcSEcCtD
Gadoversetamide—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000298	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000296	0.000296	CcSEcCtD
Gadoversetamide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000295	0.000295	CcSEcCtD
Gadoversetamide—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000295	0.000295	CcSEcCtD
Gadoversetamide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000292	0.000292	CcSEcCtD
Gadoversetamide—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000292	0.000292	CcSEcCtD
Gadoversetamide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000288	0.000288	CcSEcCtD
Gadoversetamide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000286	0.000286	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000286	0.000286	CcSEcCtD
Gadoversetamide—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000286	0.000286	CcSEcCtD
Gadoversetamide—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000283	0.000283	CcSEcCtD
Gadoversetamide—Pain—Epirubicin—peripheral nervous system neoplasm	0.000283	0.000283	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000279	0.000279	CcSEcCtD
Gadoversetamide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000277	0.000277	CcSEcCtD
Gadoversetamide—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.000275	CcSEcCtD
Gadoversetamide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.000273	CcSEcCtD
Gadoversetamide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000273	0.000273	CcSEcCtD
Gadoversetamide—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.000273	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000271	CcSEcCtD
Gadoversetamide—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.00027	0.00027	CcSEcCtD
Gadoversetamide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.000267	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000265	0.000265	CcSEcCtD
Gadoversetamide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000264	0.000264	CcSEcCtD
Gadoversetamide—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000263	0.000263	CcSEcCtD
Gadoversetamide—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000262	0.000262	CcSEcCtD
Gadoversetamide—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000262	0.000262	CcSEcCtD
Gadoversetamide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000262	0.000262	CcSEcCtD
Gadoversetamide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000262	0.000262	CcSEcCtD
Gadoversetamide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.000253	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000251	CcSEcCtD
Gadoversetamide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000244	0.000244	CcSEcCtD
Gadoversetamide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.000244	CcSEcCtD
Gadoversetamide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.000242	CcSEcCtD
Gadoversetamide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.000242	CcSEcCtD
Gadoversetamide—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000238	0.000238	CcSEcCtD
Gadoversetamide—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000234	0.000234	CcSEcCtD
Gadoversetamide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000227	CcSEcCtD
Gadoversetamide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000226	0.000226	CcSEcCtD
Gadoversetamide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.00022	CcSEcCtD
Gadoversetamide—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000219	CcSEcCtD
Gadoversetamide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000217	0.000217	CcSEcCtD
Gadoversetamide—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000211	0.000211	CcSEcCtD
Gadoversetamide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.00021	CcSEcCtD
Gadoversetamide—Rash—Epirubicin—peripheral nervous system neoplasm	0.000209	0.000209	CcSEcCtD
Gadoversetamide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000209	0.000209	CcSEcCtD
Gadoversetamide—Headache—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000208	CcSEcCtD
Gadoversetamide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.000203	CcSEcCtD
Gadoversetamide—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000197	0.000197	CcSEcCtD
Gadoversetamide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.000195	CcSEcCtD
Gadoversetamide—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000193	CcSEcCtD
Gadoversetamide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000193	CcSEcCtD
Gadoversetamide—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000192	CcSEcCtD
Gadoversetamide—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000182	CcSEcCtD
